At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Trading 12-26 09:54:24 EST
3.07
-0.01
-0.32%
High3.10Low3.05Vol22.12K
Open3.08D1 Closing3.08Amplitude1.62%
Mkt Cap15.13MTradable Cap14.28MTotal Shares4.93M
T/O68.07KT/O Rate0.48%Tradable Shares4.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Tempest Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting
Reuters  ·  12-03
Tempest Therapeutics Inc. Announces Date for Upcoming Annual Stockholder Meeting
BRIEF-Tempest Announces Closing Of Up To $8.35 Million Registered Direct Offering Of Common Stock And Concurrent Private Placement Of Warrants Priced At-The-Market Under Nasdaq Rules
Reuters  ·  11-27
BRIEF-Tempest Announces Closing Of Up To $8.35 Million Registered Direct Offering Of Common Stock And Concurrent Private Placement Of Warrants Priced At-The-Market Under Nasdaq Rules
Tempest Therapeutics Raises $8.35 Million Through Registered Direct Offering and Private Placement
Reuters  ·  11-27
Tempest Therapeutics Raises $8.35 Million Through Registered Direct Offering and Private Placement
Top Midday Decliners
MT Newswires Live  ·  11-26
Top Midday Decliners
Tempest Therapeutics Announces Private Placement of Unregistered Warrants for Up to $4.1 Million
Reuters  ·  11-25
Tempest Therapeutics Announces Private Placement of Unregistered Warrants for Up to $4.1 Million
Tempest Announces up to $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  11-25
Tempest Announces up to $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced at-the-Market Under Nasdaq Rules
Tempest Therapeutics Inc - Entered Definitive Agreement for Purchase & Sale of 1.2 Mln Common Shares at $3.625 per Share
THOMSON REUTERS  ·  11-25
Tempest Therapeutics Inc - Entered Definitive Agreement for Purchase & Sale of 1.2 Mln Common Shares at $3.625 per Share
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
Benzinga  ·  11-20
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
Tempest Therapeutics Q3 EPS USD -0.79
Reuters  ·  11-20
Tempest Therapeutics Q3 EPS USD -0.79
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today
Benzinga  ·  11-20
Why Tempest Therapeutics (TPST) Stock Is Down 45% Today
Tempest Therapeutics Announces Private Placement of Unregistered Shares
Reuters  ·  11-19
Tempest Therapeutics Announces Private Placement of Unregistered Shares
Tempest Therapeutics Inc - Matt Angel to Become President and CEO
THOMSON REUTERS  ·  11-19
Tempest Therapeutics Inc - Matt Angel to Become President and CEO
Tempest Announces Strategic Acquisition of New Dual-Car T Programs From Factor With Simultaneous Runway Extension Projected to Mid 2027
THOMSON REUTERS  ·  11-19
Tempest Announces Strategic Acquisition of New Dual-Car T Programs From Factor With Simultaneous Runway Extension Projected to Mid 2027
Tempest Therapeutics Inc - Investment Commitment to Support Operations to Mid 2027
THOMSON REUTERS  ·  11-19
Tempest Therapeutics Inc - Investment Commitment to Support Operations to Mid 2027
Tempest Therapeutics Inc: Stephen Brady to Assume Role of Chairman of Board Upon Closing of Acquisition
THOMSON REUTERS  ·  11-19
Tempest Therapeutics Inc: Stephen Brady to Assume Role of Chairman of Board Upon Closing of Acquisition
Tempest Therapeutics Inc - Stockholders to Receive One Warrant per Share
THOMSON REUTERS  ·  11-19
Tempest Therapeutics Inc - Stockholders to Receive One Warrant per Share
Tempest Therapeutics Inc: Plans to Pursue a Potential Registrational Study in Rrmm in U.S. Starting in 2027
THOMSON REUTERS  ·  11-19
Tempest Therapeutics Inc: Plans to Pursue a Potential Registrational Study in Rrmm in U.S. Starting in 2027
Tempest Therapeutics Inc - to Issue 8,268,495 Shares to Factor Affiliate, Equal to 65% of the Outstanding Shares
THOMSON REUTERS  ·  11-19
Tempest Therapeutics Inc - to Issue 8,268,495 Shares to Factor Affiliate, Equal to 65% of the Outstanding Shares
Tempest Therapeutics Inc: Will Have Global Rights to Tpst-2003 Outside of China, India, Turkey and Russia
THOMSON REUTERS  ·  11-19
Tempest Therapeutics Inc: Will Have Global Rights to Tpst-2003 Outside of China, India, Turkey and Russia
Press Release: Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
Dow Jones  ·  11-19
Press Release: Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Introduction

Company Name.
Tempest Therapeutics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Issue price:
--